Hjem › Lungekreft › Connecticut › New Haven
Kliniske studier for Lungekreft i New Haven, CT
22 studier for Lungekreft søker deltakere på steder i og rundt New Haven (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi unna
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
- og 2 flere
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
- Yale Cancer Center, New Haven
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RekruttererFase 3
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi unna
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi unna
- og 1 flere
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- Yale University, Smillow Cancer Center, New Haven
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
RekruttererFase 1
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- og 1 flere
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RekruttererFase 2
- Research Site, New Haven
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RekruttererFase 1
- Yale Cancer Center, New Haven
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RekruttererFase 1/2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekruttererFase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruttererFase 3
- Yale University School of Medicine, New Haven
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekruttererFase 1
- Yale Cancer Center, New Haven
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, New Haven
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RekruttererFase 1/2
- Yale University Cancer Center, New Haven
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi unna
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
- og 2 flere
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekruttererFase 1
- Smilow Cancer Hospital (Yale University), New Haven
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi unna
- og 1 flere
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi unna
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi unna
- og 1 flere
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
RekruttererFrivillige helsepersonell ønskes velkommen
- Yale New Haven Medical Center, New Haven
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
RekruttererObservasjonsstudie
- Yale School of Medicine, New Haven
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i New Haven
- Ikke-småcellet lungekreft41 studier
- Brystkreft37 studier
- Kreft (alle typer)33 studier
- Metastatisk kreft23 studier
- Plateepitelcancer i hode og hals22 studier
- Eggstokkreft21 studier
- Kolorektal kreft20 studier
- Prostatakreft20 studier
- Opioidoverdose18 studier
- Alkoholbrukforstyrrelse (AUD)17 studier
- Akut myelogen leukemi17 studier
- Pankreaskreft16 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.